Marthe C M Peeters1, Linda Dirven2,3, Johan A F Koekkoek2,3, Ellen G Gortmaker3, Lara Fritz3, Maaike J Vos3, Martin J B Taphoorn2,3. 1. Department of Neurology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, The Netherlands. m.c.m.peeters@lumc.nl. 2. Department of Neurology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, The Netherlands. 3. Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.
Abstract
BACKGROUND: Little is known about the symptoms glioma patients experience in the year before diagnosis, either or not resulting in health care usage. This study aimed to determine the incidence of symptoms glioma patients experienced in the year prior to diagnosis, and subsequent visits to a general practitioner (GP). METHODS: Glioma patients were asked to complete a 30-item study-specific questionnaire focusing on symptoms they experienced in the 12 months before diagnosis. For each indicated symptom, patients were asked whether they consulted the GP for this issue. RESULTS: Fifty-nine patients completed the questionnaires, 54 (93%) with input of a proxy. The median time since diagnosis was 4 months (range 1-12). The median number of symptoms experienced in the year before diagnosis was similar between gliomas with favourable and poor prognosis, i.e. 6 (range 0-24), as were the five most frequently mentioned problems: fatigue (n = 34, 58%), mental tiredness (n = 30, 51%), sleeping disorder (n = 24, 41%), headache (n = 23, 39%) and stress (n = 20, 34%). Twenty-six (44%) patients visited the GP with at least one issue. Patients who did consult their GP reported significantly more often muscle weakness (11 vs 3, p = 0.003) than patients who did not, which remained significant after correction for multiple testing, which was not the case for paralysis in hand/leg (10 vs 4), focussing (11 vs 6) or a change in awareness (9 vs 4). CONCLUSIONS: Glioma patients experience a range of non-specific problems in the year prior to diagnosis, but only patients who consult the GP report more often neurological problems.
BACKGROUND: Little is known about the symptoms gliomapatients experience in the year before diagnosis, either or not resulting in health care usage. This study aimed to determine the incidence of symptoms gliomapatients experienced in the year prior to diagnosis, and subsequent visits to a general practitioner (GP). METHODS:Gliomapatients were asked to complete a 30-item study-specific questionnaire focusing on symptoms they experienced in the 12 months before diagnosis. For each indicated symptom, patients were asked whether they consulted the GP for this issue. RESULTS: Fifty-nine patients completed the questionnaires, 54 (93%) with input of a proxy. The median time since diagnosis was 4 months (range 1-12). The median number of symptoms experienced in the year before diagnosis was similar between gliomas with favourable and poor prognosis, i.e. 6 (range 0-24), as were the five most frequently mentioned problems: fatigue (n = 34, 58%), mental tiredness (n = 30, 51%), sleeping disorder (n = 24, 41%), headache (n = 23, 39%) and stress (n = 20, 34%). Twenty-six (44%) patients visited the GP with at least one issue. Patients who did consult their GP reported significantly more often muscle weakness (11 vs 3, p = 0.003) than patients who did not, which remained significant after correction for multiple testing, which was not the case for paralysis in hand/leg (10 vs 4), focussing (11 vs 6) or a change in awareness (9 vs 4). CONCLUSIONS:Gliomapatients experience a range of non-specific problems in the year prior to diagnosis, but only patients who consult the GP report more often neurological problems.
Authors: Lasse Dührsen; Thomas Sauvigny; Franz L Ricklefs; Klaus-Christian Mende; Miriam Schaper; Jakob Matschke; Einar Goebell; Manfred Westphal; Tobias Martens Journal: Epilepsia Date: 2018-12-09 Impact factor: 5.864
Authors: Ingeborg Bosma; Maaike J Vos; Jan J Heimans; Martin J B Taphoorn; Neil K Aaronson; Tjeerd J Postma; Henk M van der Ploeg; Martin Muller; W Peter Vandertop; Ben J Slotman; Martin Klein Journal: Neuro Oncol Date: 2006-10-03 Impact factor: 12.300
Authors: Edgar G Dawson; Linda E A Kanim; Parveen Sra; Frederick J Dorey; Theodore B Goldstein; Rick B Delamarter; Harvinder S Sandhu Journal: Spine (Phila Pa 1976) Date: 2002-05-01 Impact factor: 3.468
Authors: Emma van Kessel; Anniek E Baumfalk; Martine J E van Zandvoort; Pierre A Robe; Tom J Snijders Journal: J Neurooncol Date: 2017-05-31 Impact factor: 4.130
Authors: Mio Ozawa; Paul M Brennan; Karolis Zienius; Kathreena M Kurian; William Hollingworth; David Weller; Willie Hamilton; Robin Grant; Yoav Ben-Shlomo Journal: Fam Pract Date: 2018-09-18 Impact factor: 2.267
Authors: Svenja Kopelke; Troels W Kjaer; Soeren Tvilsted; Steven E Schild; Tobias Bartscht; Dirk Rades Journal: In Vivo Date: 2022 Jan-Feb Impact factor: 2.155
Authors: Michael Weller; Martin van den Bent; Matthias Preusser; Emilie Le Rhun; Jörg C Tonn; Giuseppe Minniti; Martin Bendszus; Carmen Balana; Olivier Chinot; Linda Dirven; Pim French; Monika E Hegi; Asgeir S Jakola; Michael Platten; Patrick Roth; Roberta Rudà; Susan Short; Marion Smits; Martin J B Taphoorn; Andreas von Deimling; Manfred Westphal; Riccardo Soffietti; Guido Reifenberger; Wolfgang Wick Journal: Nat Rev Clin Oncol Date: 2020-12-08 Impact factor: 66.675